Open AccessCOVID-19 and gastroenteric manifestations
Author(s) -
Zhang-Ren Chen,
Jing Liu,
Zhi-Guo Liao,
Jian Zhou,
Hongwei Peng,
Fei Gong,
Jinfang Hu,
Ying Zhou
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i19.4990
Subject(s) - medicine , covid-19 , coronavirus , pandemic , transmission (telecommunications) , virology , feces , disease , infectious disease (medical specialty) , outbreak , biology , microbiology and biotechnology , electrical engineering , engineering
Coronavirus disease 2019 (COVID-19), caused by the infection of a novel coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)], has become a pandemic. The infection has resulted in about one hundred million COVID-19 cases and millions of deaths. Although SARS-CoV-2 mainly spreads through the air and impairs the function of the respiratory system, it also attacks the gastrointestinal epithelial cells through the same receptor, angiotensin converting enzyme 2 receptor, which results in gastroenteric symptoms and potential fecal-oral transmission. Besides the infection of SARS-CoV-2, the treatments of COVID-19 also contribute to the gastroenteric manifestations due to the adverse drug reactions of anti-COVID-19 drugs. In this review, we update the clinical features, basic studies, and clinical practices of COVID-19-associated gastroenteric manifestations.